EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A metabolomic signature of weight-loss and its associations with BMI-linked diseases: A post-hoc analysis of two intervention trials and a Mendelian randomisation study

Nicholas Sunderland iD, Madeleine L Smith, Alex McConnachie iD, Paul Welsh iD, Roy Taylor iD, Michael E J Lean iD, Chris A Rogers iD, Jane M Blazeby iD, Naveed Sattar iD, Lavinia Paternoster iD, R Thomas Lumbers iD, Nicholas J Timpson iD und 1 weitere

PLOS Medicine · 04.11.2026 · 23 (11) · e1005290

DOI: 10.1371/journal.pmed.1005290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 04.11.2026. Verfasst von Nicholas Sunderland und 12 weiteren Autor:innen. Beteiligte Einrichtung: MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Weight Loss, Body Mass Index, Obesity, Metabolomics. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a major risk factor for a broad spectrum of diseases, yet the molecular pathways underlying this risk remains poorly understood. Individual analytical approaches—interventional trials, observational data, and genetic methods—are each susceptible to distinct sources of bias. We aimed to identify a common metabolic perturbation signature of adiposity by triangulating evidence across multiple sources of body mass index (BMI) variation, and to characterise associations between this signature and contrasting adiposity-linked disease outcomes. Methods and findings We integrated mass spectrometry and nuclear magnetic resonance metabolomic profiling from two weight-loss interventions—a structured diet programme (DiRECT trial, ISRCTN03267836) and metabolic and bariatric surgery (By-Band-Sleeve trial, ISRCTN00786323)—with mendelian randomisation (MR) estimates of the effect of lifetime BMI exposure on metabolite levels, in order to identify a consistent BMI-associated metabolite signature across sources with distinct error structures. Weight loss-associated metabolites were then instrumented using genetic variants and their associations with heart failure (HF), osteoarthritis, and kidney cancer estimated in a two-sample MR framework, with instruments grouped into clusters based on genetic similarity to aid biological interpretation. 242 metabolites were consistently altered across weight loss interventions, predominantly comprising lipids, lipoproteins, and amino acids. The majority of these showed concordant associations with lifetime BMI in MR, consistent with regulation by adiposity. Differential components of this signature were associated with disease-specific outcomes. For HF, low-density lipoprotein (LDL) measures were strongly associated with increased risk, consistent with ischaemic aetiology enrichment, whilst high-density lipoprotein (HDL) cholesterol-enrichment traits were protective, and markers of dysfunctional HDL remodelling were associated with increased risk. For osteoarthritis, lipoprotein associations were again associated with disease risk but in the opposite direction to that seen with HF; additional signals were observed in glycine metabolism pathways. For kidney cancer, the adiposity metabolite signature translated poorly into disease associations, with only 5-methyluridine and ursodeoxycholate associations identified. The main limitations of our study include the potential for residual horizontal pleiotropy with metabolite instruments despite multiple sensitivity analyses and the rank-normalised scale of metabolite measures, which limits direct physiological interpretability.

Conclusions

Triangulating evidence across dietary intervention, metabolic and bariatric surgery, and MR of lifetime BMI identified a robust metabolic signature of adiposity. The association of components of this signature with obesity-related outcomes was disease-specific, supporting the notion that not all adiposity-associated metabolic perturbations are uniformly relevant across the spectrum of obesity-related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossBody Mass IndexObesityMetabolomicsMetabolomeHumansMendelian Randomization AnalysisBariatric SurgeryAdiposityMaleFemale

Autor:innen und Institutionen

  • MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Population Health Sciences, University of Bristol, Bristol, United Kingdom.
  • Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • Newcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

ORCID-Profile: Nicholas Sunderland, Alex McConnachie, Paul Welsh, Roy Taylor, Michael E J Lean, Chris A Rogers, Jane M Blazeby, Naveed Sattar, Lavinia Paternoster, R Thomas Lumbers, Nicholas J Timpson, Laura J Corbin

Förderung

  • NHLBI NIH HHS
  • Wellcome Trust
  • Medical Research Council
  • Health Technology Assessment Programme
  • NIHR Bristol Biomedical Research Centre
  • Strategic Research Initiative by Diabetes UK
  • UCLH Biomedical Research Centre
  • British Heart Foundation

Zitieren

APA

Sunderland, N., Smith, M. L., McConnachie, A., Welsh, P., Taylor, R., Lean, M. E. J., Rogers, C. A., Blazeby, J. M., Sattar, N., Paternoster, L., Lumbers, R. T., Timpson, N. J., & Corbin, L. J. (2026). A metabolomic signature of weight-loss and its associations with BMI-linked diseases: A post-hoc analysis of two intervention trials and a Mendelian randomisation study. PLOS Medicine, 23(11), e1005290. https://doi.org/10.1371/journal.pmed.1005290

Vancouver

Sunderland N, Smith ML, McConnachie A, Welsh P, Taylor R, Lean MEJ, et al. A metabolomic signature of weight-loss and its associations with BMI-linked diseases: A post-hoc analysis of two intervention trials and a Mendelian randomisation study. PLOS Medicine. 2026;23(11):e1005290. doi:10.1371/journal.pmed.1005290

BibTeX
@article{Sunderland2026,
  author = {Sunderland, Nicholas and Smith, Madeleine L and McConnachie, Alex and Welsh, Paul and Taylor, Roy and Lean, Michael E J and Rogers, Chris A and Blazeby, Jane M and Sattar, Naveed and Paternoster, Lavinia and Lumbers, R Thomas and Timpson, Nicholas J and Corbin, Laura J},
  title = {A metabolomic signature of weight-loss and its associations with BMI-linked diseases: A post-hoc analysis of two intervention trials and a Mendelian randomisation study},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {11},
  pages = {e1005290},
  doi = {10.1371/journal.pmed.1005290}
}
Kostenlos starten →